Skip to main content

Day: August 13, 2024

Element Reports Record Second Quarter Results, Raises Full-Year 2024 Guidance, and Announces Strategic Acquisition

Amounts in US$ unless otherwise noted Record quarterly net revenue of US$274.6 million driving adjusted EPS of US$0.29 and adjusted free cash flow per share of US$0.38 Robust net revenue growth of 14.1% year-over-year led by a double-digit increase across net financing and services revenues; and up 4.6% from a strong Q1 2024 Reports record origination volume; up 28.2% from Q1 2024 and up 4.6% from Q2 2023 Raises full-year 2024 guidance on most metrics as a result of robust first half 2024 performance Unveils first-ever Purpose statement: Move the World Through Intelligent Mobility Accelerates digitization and automation capabilities with the execution of a definitive agreement for the acquisition of Autofleet Solutions Ltd. (“Autofleet”) TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Element Fleet Management Corp....

Continue reading

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibody Entered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. “We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M,” said Bronson Crouch, CEO of Instil. “By executing a 15-year lease of our Tarzana cell therapy manufacturing facility, we have strengthened our financial foundation...

Continue reading

DZS Completes Restatement of 2022 and Q1 2023 Financial Results and Files Reports for Remaining Periods in 2023

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — DZS (OTC: DZSI), a developer of Network Edge, Connectivity and Cloud Software solutions enabling gigabit broadband everywhere, today announced that it has filed with the SEC its restated financial results for the periods from the first quarter of 2022 through the first quarter of 2023 as well as its remaining periods in 2023. DZS is now current with its Form 10-Q and 10-K filings with the SEC through 2023. “We took an extremely thorough approach to the restatement process, and now have completed the restatements with respect to 2022 and the first quarter of 2023, as well as the reports for the remaining periods in 2023,” said Charlie Vogt, President and CEO, DZS. “Following a strong top line revenue growth environment in 2021 and 2022, 2023 represented a challenging market and business environment....

Continue reading

Credicorp Ltd.: Credicorp Corrects Certain Accumulated Ratios in 2Q24 Earnings Materials and Reaffirms 1H24 Financials and 2024 Guidance

Lima, Aug. 13, 2024 (GLOBE NEWSWIRE) — Lima, PERU, August 13, 2024 – Credicorp Ltd. (“Credicorp” or “the Company”) (NYSE: BAP | BVL: BAP) announces to its shareholders and the market, corrections to four ratios published in its 2Q24 Earnings Materials. These amendments are attributable to miscalculations on certain accumulated performance indicators. Below is a table including the reported and corrected indicators, presented on the Company´s 2Q24 Earnings Release. Performance Indicator Originally Reported Figure Corrected Figure Location in Earnings Release 1H24 ROE 17.2% 17.6% Pages 3 and 11 1H24 Funding cost 3.16% 2.90% Page 11 1H24 Operating expenses / Total average assets 7.4% 3.7% Page 11 1H23 Operating Expenses / Total average assets 7.1% 3.5% Page 11 The above-mentioned corrections do not affect the Company’s...

Continue reading

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025

Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ATI-1701 funding commitments from U.S. Air Force Academy and interactions with the U.S. Food and Drug Administration, confirming the development pathway through IND submission U.S. Food and Drug Administration meeting request submitted to discuss ATI-1801 registration strategy HALIFAX, Nova Scotia, Aug. 13, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2025, which ended on June 30, 2024. All figures are stated in Canadian...

Continue reading

Etrion Releases Second Quarter 2024 Results

GENEVA, Aug. 13, 2024 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”, and, together with its subsidiaries, the “Group”) released today its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and six months ended June 30, 2024. Q2-24 HIGHLIGHTS Etrion closed the second quarter of 2024 with an unrestricted cash balance of US$5.9 million and a positive working capital of US$5.6 million. Management Comments: Marco A. Northland, the Company’s Chief Executive Officer, commented, “The Company going forward will maintain very limited resources and proceed with a windup of the Company as previously disclosed.” FINANCIAL SUMMARY   Three months ended Six months ended US$ thousands (unless otherwise stated) Q2-24 Q2-23 Q2-24 Q2-23           Financial...

Continue reading

K92 Mining Announces 2024 Q2 Financial Results – Strong Financial Position and Stage 3 and 4 Expansions Fully Financed

VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three and six months ended June 30, 2024. Production Quarterly production of 24,347 ounces gold equivalent (“AuEq”) or 21,661 oz gold, 1,246,639 lbs copper and 26,754 oz silver (1). Production for the quarter was impacted by the temporary suspension of operations as previously announced. Cash costs of US$919/oz gold and all-in sustaining costs (“AISC”) of US$1,510/oz gold (2). Strong metallurgical recoveries in Q2 of 93.7% gold and 95.3% copper, representing the highest gold recoveries since Q4 2019 and record quarterly recoveries to date for copper. Quarterly ore processed of 95,582 tonnes and total ore mined of 99,209 tonnes, with long hole open stoping...

Continue reading

Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results

SALINAS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces unaudited revenue and operating results for the second quarter of 2024 (ended June 30, 2024). All figures stated are in US Dollars. Second Quarter Financial Highlights: Net revenue generated for the quarter ended June 30, 2024 decreased 50% to $3.5 million, as compared to $7.0 million for the second quarter last year. Net revenue decreased 27% from $4.9 million in the first quarter of 2024. CPG revenue decreased 11% for the quarter ended June 30, 2024 compared to the quarter ended June 30, 2023 and decreased 15% compared to the first quarter of 2024. Bulk Product...

Continue reading

Clairvest Reports Fiscal 2025 First Quarter Results

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Clairvest Group Inc. (TSX: CVG) today reported results for the fiscal 2025 first quarter ended June 30, 2024 and events which occurred subsequent to quarter end. (All figures are in Canadian dollars unless otherwise stated) Highlights June 30, 2024 book value was $1,186.2 million or $81.02 per share compared with $1,176.3 million or $80.16 per share as at March 31, 2024 Net income for the quarter ended June 30, 2024 was $23.9 million or $1.63 per share Clairvest and Clairvest Equity Partners VI (“CEP VI”) made two platform investments during the quarter to complete the CEP VI Fund investment program and Clairvest commenced the CEP VII investment program Clairvest and Clairvest Equity Partners V (“CEP V”) completed the sale of Durante Rentals Subsequent to quarter end, Clairvest, CEP V...

Continue reading

AirBoss Reports 2nd Quarter 2024 Results

NEWMARKET, Ontario, Aug. 13, 2024 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company” or “AirBoss”) today announced its second quarter 2024 results. The Company will host a conference call and webcast to discuss the results on August 14th at 9:00 a.m. (ET), the details of which are outlined below. All dollar amounts are shown in thousands of United States dollars (“US $” or “$”), except per share amounts, unless otherwise noted. Recent Highlights Commenced shipments in the third quarter of 2024 under AirBoss Manufactured Products’ defense business’ recently-announced contract valued at up to $45 million to provide its Bandolier multipurpose energetic system to a NATO partner nation; Declared a quarterly dividend of C$0.035 per common share; Retained TD Securities Inc....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.